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Abstract Pyrrolidine dithiocarbamate (PDTC) is a potent
inhibitor of nuclear factor kappa B (NF-UB) activation. PDTC
inhibited basal NF-UB activity of endothelial cells. PDTC,
however, failed to inhibit basal NF-UB activity after withdrawal
of serum in the media, and the inhibitory effect of PDTC could
be restored by addition of zinc. When various preparations of
metal ion-EDTA were tested with PDTC in serum-containing
media, only Zn-EDTA failed to block the inhibitory effect of
PDTC. The dependence on zinc was also noted in PDTC
inhibition of NF-UB stimulated by TNFK. These facts suggest
that zinc is required for PDTC inhibition of NF-UB activation.
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1. Introduction
Dithiocarbamates were widely used in agriculture as insec-
ticides and fungicides [1] and in health care for the manage-
ment of alcoholism and metal intoxication [2]. Recently, di-
thiocarbamates have also been proposed for treating acquired
immunode¢ciency syndrome and cancer [3,4]. Pyrrolidine di-
thiocarbamate (PDTC), one of dithiocarbamates, is cytotoxic
in a number of cell types [5^8], in some cases presumably due
to its potent inhibitory e¡ect on NF-UB activity [8]. NF-UB
activation is responsive to reactive oxygen species (ROS) [9].
ROS scavengers such as dithiocarbamates [10], vitamin E de-
rivatives [11] and N-acetyl-L-cysteine [12] prevent the NF-UB
activation. PDTC inhibition of NF-UB has been attributed to
its antioxidant property [13]. PDTC is also a metal chelator.
Thus, removal of metal ions has been known to be an alter-
native mechanism of action for PDTC inhibition of NF-UB
activity [10,13]. In contrast to these well-known properties of
PDTC, Nobel et al. [6] showed that PDTC increased intra-
cellular copper level. They suggested that pro-apoptotic e¡ect
of PDTC could be mediated by these redox-active copper
ions. Hence, intriguing possibility that the inhibitory e¡ect
of PDTC on NF-UB may involve its interaction with metal
ions remains to be con¢rmed. In fact, several metal ions have
been shown to modulate NF-UB activity. Copper inhibits IUB
phosphorylation which is an upstream event in NF-UB acti-
vation [14]. Gold, an anti-rheumatic drug, blocks DNA bind-
ing activity of NF-UB [15]. In vitro, chromium, cadmium,
mercury, zinc, and arsenite also inhibit NF-UB activity [16].
However, the exact role of zinc in NF-UB activity has re-
mained clouded by con£icting observations. Zinc was noted
to be either essential for [15,17] or to exert [16,18] an inhib-
itory e¡ect on NF-UB activity. None of these studies, how-
ever, addressed the role of zinc in PDTC inhibition of NF-UB
activity. Results from the present study show that zinc is
required for inhibitory action of PDTC on NF-UB.
2. Materials and methods
2.1. Materials
Pyrrolidine dithiocarbamate (PDTC) was purchased from Sigma
(St. Louis, MO, USA). Free base EDTA, copper-saturated EDTA
(Cu-EDTA), calcium-saturated EDTA (Ca-EDTA), and zinc-satu-
rated EDTA (Zn-EDTA) were purchased from Fluka (Buchs, Switzer-
land). All metal-saturated EDTAs are disodium EDTA saturated with
equimolar respective metal. Double-stranded oligonucleotides con-
taining consensus NF-UB binding sequence and its mutant form
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Poly(dIdC) was purchased from Pharmacia (Uppsala, Sweden).
[Q-32P]ATP was from DuPont NEN (Boston, MA, USA). Speci¢c
antisera to p50 and p65 were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). Fetal bovine serum (FBS) was purchased
from Hyclone (Logan, UT, USA). Cell culture products were pur-
chased from Gibco BRL (Life Technologies, NY, USA).
2.2. Cell cultures
Bovine cerebral endothelial cells (BCECs) were prepared and char-
acterized as previously described [19,20] with modi¢cation [21]. Endo-
thelial cells of passages 4^15, which were uniformly positive for factor
VIII and vimentin (s 95% endothelial cells) and exhibited the char-
acteristic bradykinin receptors, were grown to 70^80% con£uence in
Dulbecco’s modi¢ed Eagle’s medium (DMEM) containing 10% FBS
before experiments. PC12 (ATCC CRL 1721) was grown in DMEM
supplemented with 10% FBS and 5% horse serum.
2.3. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared according to the method described
by Lee et al. [22] with modi¢cation [23]. For EMSA, the following
oligonucleotide with the NF-UB consensus binding sequence was
used: (5P-AGTTGAGGGGACTTTCCCAGGC-3P). A mutant motif
with G to C substitution (5P-AGTTGAGGCGACTTTCCCAGGC-
3P) served as a control. Labeling of the oligonucleotide with
[Q-32P]ATP and the EMSA method have been previously detailed
[23]. Reactions were started by addition of nuclear extracts and al-
lowed for 30 min at room temperature. Samples were loaded on 4%
polyacrylamide non-denaturing gel and electrophoresed for 2 h at
180 V. The dried gel was exposed to Kodak XR5 ¢lm on intensifying
screen for 10^20 h at 370‡C. For competition assay, an unlabeled
NF-UB oligonucleotide was added in 100-fold excess. For supershift
assay, 1 Wl of anti-p65 or anti-p50 antibody was incubated with nu-
clear extract for 30 min at room temperature prior to binding reac-
tion.
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3. Results
3.1. E¡ect of PDTC on NF-UB activity in BCECs
Basal NF-UB activity was present in BCECs which were
maintained in DMEM containing 10% FBS. To ensure that
the mobility shift bands under this condition were the NF-UB/
oligonucleotide complex, we used an NF-UB mutant oligonu-
cleotide with a ‘G’C‘C’ substitution in the NF-UB binding
motif as a control. Addition of this cold NF-UB mutant oli-
gonucleotide (100-fold in excess) did not a¡ect the bands (p50/
p65 and p50/p50) which were associated with the labeled NF-
UB oligonucleotide probe; whereas the cold consensus NF-UB
oligonucleotide (100-fold in excess) completely abolished these
bands (Fig. 1A). AP-1 or Oct-1 consensus oligonucleotide also
failed to displace the labeled NF-UB oligonucleotide probe
(Fig. 1A). Incubation of nuclear extracts with antisera against
NF-UB p50 or p65 subunit respectively caused a supershift of
the corresponding NF-UB/oligonucleotide band (Fig. 1B).
These results established the speci¢city of the NF-UB binding
activity assay. In a time course study, PDTC (50 WM) inhib-
ited the basal NF-UB activity almost completely in 3 h when
BCECs were grown in DMEM enriched with 10% FBS (Fig.
1C). In subsequent experiments, we determined NF-UB bind-
ing activity 4 h after PDTC treatment. PDTC inhibited NF-
UB activity in serum-fed BCECs in a dose-dependent manner
(25^100 WM) (Fig. 1D). In the absence of serum, PDTC, in
concentrations up to 1 mM, failed to alter NF-UB activity
(Fig. 1E).
3.2. E¡ect of metal ions on PDTC action
To determine whether selected factor(s) in serum might be
required for PDTC action, we investigated selected metal ions
including iron, copper and zinc which are likely to a¡ect NF-
UB binding activity. BCECs deprived of serum were exposed
to PDTC with or without one of the selected metal ions for
4 h. Each metal was prepared freshly just prior to experiment.
FeSO4 failed to restore the inhibitory e¡ect of PDTC on NF-
UB activity (Fig. 2A). ZnSO4, at concentrations as low as
1 WM when co-administered with PDTC, completely blocked
NF-UB activity under the serum-deprived condition (Fig.
2A). CuSO4 showed a similar e¡ect as ZnSO4, but at a
much higher concentration (50 WM). If a speci¢c metal ion
(zinc or copper) is responsible for the lack of PDTC e¡ect in
the absence of serum, chelating the selected metal ion(s) in
serum should block PDTC inhibition of NF-UB activity.
This approach was tested using Ca-, Cu- and Zn-EDTA.
Each of these metal ion-EDTA complexes chelates metal
ions other than the particular ion that forms the complex
with EDTA. Thus, Zn-EDTA chelates metal ions other than
Zn. When various preparations of metal ion-EDTA were
compared simultaneously, the biological e¡ect of a certain
metal ion may be distinguished from the non-e¡ective ones
[24]. PDTC, at a concentration of 50 WM, was added with one
of the three metal ion-EDTA preparations for 4 h under se-
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Fig. 1. E¡ect of PDTC on NF-UB activation in BCECs. Nuclear ex-
tracts were obtained 4 h after PDTC or vehicle treatment followed
by EMSA. Basal NF-UB activity was present in BCECs grown in
DMEM containing 10% FBS (Con). A: Competition for NF-UB
binding with cold nucleotides (wild-type (wt-) or mutant (mt-) NF-
UB, AP-1 or Oct-1) which were in excess of 100-fold. B: Supershift
with anti-p65 or anti-p50 IgG. Arrowhead denotes the non-speci¢c
band (n.s.). C: A time course of NF-UB inhibition by PDTC (50
WM). D: Dose-dependent inhibition of NF-UB by PDTC in DMEM
containing 10% FBS. E: Lack of PDTC e¡ect on NF-UB activity in
serum-deprived BCECs.
Fig. 2. E¡ects of selected metals on PDTC inhibition of NF-UB ac-
tivity. A: BCECs were treated with various concentrations of
CuSO4, FeSO4 or ZnSO4; plus PDTC (50 WM) for 4 h after serum
withdrawal. B: PDTC was co-administered with the indicated con-
centrations of Ca-EDTA to BCECs grown in the DMEM contain-
ing 10% FBS. C: Free base, Ca-, Cu- or Zn-EDTA (each 10 WM)
and PDTC (50 WM) were added together to BCECs grown in
DMEM containing 10% FBS.
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rum-enriched condition (DMEM containing 10% FBS) in
which PDTC has been shown above to inhibit basal NF-UB
activity. The inhibitory e¡ect of PDTC on NF-UB activity
under this condition was abolished by Ca-EDTA in a dose-
dependent manner (Fig. 2B). At 10 WM, Ca-EDTA almost
completely blocked the inhibitory e¡ect of PDTC (Fig. 2B
and C). Free base EDTA and Cu-EDTA, at a concentration
of 10 WM, had a similar e¡ect (Fig. 2C). However, Zn-EDTA
failed to block PDTC inhibition of basal NF-UB activity at
this concentration (Fig. 2C). None of the metal ion-EDTA
preparations alone had any e¡ect on the basal NF-UB activity
(data not shown).
3.3. E¡ect of PDTC on TNFK-stimulated NF-UB activation
Treatment of BCECs with TNFK (5 ng/ml) for 3 h resulted
in an increase in NF-UB activity. TNFK activation of NF-UB
was evident with or without serum in the medium (Fig. 3A).
However, PDTC (25 WM) inhibition of NF-UB activity in-
duced by TNFK (5 ng/ml) was detected only in the presence
of serum (Fig. 3A, left panel, the left three lanes). The same
concentration of PDTC failed to inhibit NF-UB activation by
TNFK upon serum withdrawal (Fig. 3A, left panel, the right
three lanes). In PC12 cells, minimal basal NF-UB activity was
detected. TNFK (5 ng/ml) increased NF-UB activation within
30 min with or without serum (Fig. 3A, middle panel). The
p65 and p50 subunits were present in the shifted complexes
(Fig. 3A, right panel). PDTC (50 WM) inhibited TNFK-stimu-
lated NF-UB activity in PC12 cells in the presence of serum
(Fig. 3A, middle panel, the left three lanes). PDTC was with-
out inhibitory action upon serum withdrawal (Fig. 3A, middle
panel, the right three lanes). The ability of PDTC to inhibit
TNFK (5 ng/ml) activation of NF-UB was abolished by Ca-
EDTA (20 WM), but not Zn-EDTA (20 WM), in BCECs (Fig.
3B, left panel) and PC12 cells (Fig. 3B, right panel). Other
forms of EDTA such as free base EDTA or Cu-EDTA also
blocked PDTC inhibition of TNFK-stimulated NF-UB activa-
tion in both BCECs and PC12 cells (data not shown).
3.4. E¡ect of thiol or non-thiol antioxidants on NF-UB activity
and PDTC action
We tested the e¡ects of thiol or non-thiol antioxidants on
basal NF-UB activities of endothelial cells. Nuclear extracts of
BCECs were obtained after 4 h of treatments of antioxidants
or PDTC plus antioxidants. Non-thiol antioxidants such as
trolox (1 mM), butylated hydroxyanisole (BHA; 500 WM) and
ascorbic acid (1 mM) and thiol antioxidants such as dihydro-
lipoic acid (DHLA) and N-acetyl-L-cysteine (NAC) themselves
did not change the basal NF-UB activation (Fig. 4A, ¢rst
lanes from right of upper and lower panels of Fig. 4B). How-
ever, thiol antioxidants prevented the inhibitory action of
PDTC (Fig. 4B). In contrast, non-thiol antioxidants did not
a¡ect the NF-UB inhibition by PDTC (data not shown).
4. Discussion
In the present study, PDTC inhibited basal NF-UB activity
in BCECs under serum-enriched conditions. However, it did
not alter NF-UB activation signi¢cantly when serum was ab-
sent in media. It was reasonable to speculate that certain
factor(s) in serum might be required for the inhibitory e¡ect
of PDTC on NF-UB activity. Recently, selected metal ions
have emerged as important regulators of NF-UB activity
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Fig. 4. E¡ect of thiol or non-thiol antioxidant on NF-UB activity
and PDTC action. BCECs were treated with antioxidants or anti-
oxidants plus PDTC in serum-containing media. A: BCECs were
treated with non-thiol antioxidants, trolox (1 mM), BHA (500 WM)
or ascorbic acid (1 mM), for 4 h. Second lane represents inhibition
of NF-UB by 4 h treatment of 50 WM PDTC. B: BCECs were
treated with thiol antioxidants or PDTC (50 WM) plus thiol anti-
oxidants for 4 h.
Fig. 3. E¡ect of PDTC on TNFK activation of NF-UB activity. A:
BCECs were treated with TNFK (5 ng/ml) for 2 h in the presence
or absence of 10% FBS in the medium with or without PDTC (50
WM) (left). PC12 cells were preincubated with PDTC (50 WM) for
30 min, followed by TNFK (5 ng/ml) treatment for 30 min in the
presence or absence of 10% FBS (middle). Supershift assay was
done with anti-p65 or anti-p50 IgG (right). B: BCECs were treated
with TNFK (5 ng/ml). PDTC (25 WM) with or without Ca-EDTA
(20 WM) or Zn-EDTA (20 WM) was co-administered with TNFK for
3 h in DMEM containing 10% FBS. PC12 cells were preincubated
with PDTC (50 WM) plus Ca-EDTA (20 WM) or Zn-EDTA (20
WM), followed by treatment with TNFK (5 ng/ml). Arrowheads de-
note non-speci¢c bands.
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[14^16]. We explored the possibility that metals ions that are
known to be present in serum could be the factor(s) required
for PDTC action. Among copper, zinc and iron, copper and
zinc restored the inhibitory e¡ect of PDTC on NF-UB under
serum deprivation. As reported previously, PDTC increased
intracellular copper level in several cell types [6,25]. The mech-
anism was suggested as that PDTC formed lipophilic complex
with copper ion [6]. Thus, metal ion that could be available
for PDTC action would not be necessarily free from. How-
ever, in BCEC examined in the present study, the concentra-
tions of copper (50 WM or above) required for PDTC action
were much higher than the concentration of copper that is
expected to be normally present in serum. In contrast, zinc
restored PDTC action in serum-deprived cells at concentra-
tions as low as 1 WM, which was equivalent to the degree of
inhibition by the same concentration of PDTC in serum con-
dition. To verify that zinc is the dominant metal ion that is
essential for the inhibitory action of PDTC, various prepara-
tions of metal ion-EDTA complex were tested. Cu-EDTA or
Zn-EDTA can chelate metal ions in serum-containing media
without lowering the concentration of respective metal ion
that is the constituent of the metal ion-EDTA complex [24].
Thus, it is possible to determine the relative potency of these
metal ions in their possible contribution to PDTC inhibition
of NF-UB activity. In BCECs, NF-UB inhibition by PDTC
could be completely abolished by free base EDTA, Ca-
EDTA or Cu-EDTA. However, Zn-EDTA failed to block
the inhibitory e¡ect of PDTC. Moreover, under selected ex-
perimental paradigms, Zn-EDTA actually potentiated the in-
hibitory e¡ect of PDTC on NF-UB probably because of the
release of zinc ion from the Zn-EDTA complex (Fig. 3B). It is
plausible that zinc is an essential element in the PDTC inhib-
ition of NF-UB activation. The notion that zinc is the serum
factor that is required for PDTC inhibition of NF-UB activity
could also be extended to PDTC inhibition of TNFK-induced
NF-UB activation. We explored this scheme of zinc-mediated
PDTC inhibition of NF-UB in other cell types. We found that
zinc was also required in PDTC inhibition of NF-UB activity
in PC12. In NIH/3T3, Hep 3B and HeLa cell, this paradigm
was also applicable (unpublished data).
We have previously shown that PDTC was cytotoxic to
BCECs by mediation of zinc ion [26]. Since NF-UB is known
to promote cell viability [27^30], it would be entertained that
PDTC-induced cell death may be related to its inhibition of
NF-UB activity. Other studies also reported that PDTC in-
duced apoptosis in B-lymphoma cell [8] and rendered T-lym-
phoma cell susceptible to apoptosis [31] by suppression of
basal NF-UB activities. In BCECs, NF-UB activity was com-
pletely inhibited by PDTC in 3 h in the present study which
was followed by apparent cell death after 6 h in our previous
study [26]. Future study using experimental design for selec-
tive inhibition of NF-UB will support a cell death scheme in
which PDTC induction of BCEC death is secondary to zinc-
mediated inhibition of NF-UB activity.
PDTC has been extensively used as a NF-UB inhibitor. The
molecular basis for the action of PDTC has been claimed to
be due to its antioxidant or metal chelator activity [10,13].
The dithiocarboxyl group on PDTC is expected to exert anti-
oxidant e¡ect [13]. Previously we showed that PDTC in-
creased the intracellular zinc that was recruited from extra-
cellular source [26]. In the present study, the inhibitory e¡ect
of PDTC on NF-UB activity was abolished when extracellular
metal ions were chelated by membrane non-permeable chela-
tors. Furthermore, thiol or non-thiol antioxidants did not
a¡ect NF-UB activation in BCECs. It is noteworthy that thiol
antioxidants in contrary to non-thiol antioxidant, when co-
administered with PDTC, rather abolished the inhibitory ac-
tion of PDTC. This seems to be a result of direct interaction
of zinc with thiol moiety [32]. Thus, at least in the cell types
we studied, NF-UB inhibition by PDTC is unlikely to be due
to simple chelation of metal ions or direct scavenging of re-
active oxygen species by certain functional moiety of PDTC.
The fact that PDTC is a far more potent NF-UB inhibitor as
compared to most antioxidants, also suggests that interaction
with zinc, but not the antioxidative e¡ect, is the likely mech-
anism of PDTC e¡ects on NF-UB activity. This study also
implies that zinc would be an important negative regulator
of NF-UB in certain physiologic or pathologic condition.
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